Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a nanostructured lipid carrier gel containing Minoxidil and Finasteride met desired criteria for stability and performance, suggesting it may be an effective topical treatment for hair loss, especially in extreme conditions.

This study reported that compound 16 (olean-12-en-3beta-ol, cinnamate) from Merremia peltata showed potential as an androgen receptor antagonist, suggesting it may benefit alopecia treatment based on molecular docking and ADME-Tox predictions.

This study found that Lophocereus marginatus extracts significantly inhibited melanoma cell growth in vitro and stimulated hair growth in mice, with combined treatments of LM with minoxidil or bergamot showing notable effects by day 14 without altering body weight.

This study found that L-borneol, derived from Chinese medicine, significantly promotes the differentiation of rat hair follicle stem cells into basal layer cells, aiding wound healing, with the process involving inhibition of the PODXL2 gene by the microRNA rno-miR-127.

This study optimized the reaction conditions for the stereoselective hydrogenation of a compound used in manufacturing finasteride and dutasteride, improving the selectivity for the desired isomer.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.

The researchers reported that compounds 11 to 13 derived from Westphalen-type steroids showed strong antiandrogenic activity in vivo, though their effects could not be attributed to 5α-reductase inhibition or androgen receptor binding.

This study found that Lepidium sativum seed extract showed potential in treating alopecia in rats by reducing 5(alpha)-dihydrotestosterone levels and improving hair length compared to minoxidil.

This study developed and validated a label-free assay using LC-MS to screen for S5αR inhibitors, identifying Thai herbal extracts, Impatiens balsamina L. and Curcuma longa L., as promising sources.

This study reports a new industrial process for making finasteride using novel protective groups, demonstrated through spectral data of newly prepared compounds.

In this study, researchers tested lotions containing DGLA, S-equol, and propionyl-l-carnitine on individuals with androgenic alopecia, noting a significant increase in hair count for women and a marginal increase for men after 6 months, along with improved hair cycle dynamics.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

This study suggests that spironolactone-loaded nanostructured lipid carriers could enhance follicular delivery and offer a more localized treatment for androgenic alopecia, potentially reducing systemic side effects.

This research found that Leydig cells significantly rely on synthesizing omega-6 HUFAs to support male steroid hormone production, highlighting a new role for these fatty acids in the male reproductive system.

This study introduced a novel nonsteroidal androgen receptor antagonist that effectively controls sebum production in the golden Syrian hamster ear model through targeted follicular delivery.

This promotional content discusses Locerin as a hair growth supplement but reports no research findings; readers are encouraged to explore their own conclusions.

This paper describes the synthesis of (16S,20S)-3β-hydroxy-5α-pregnane-20,16-carbolactam from tigogenin without presenting new experimental results.

In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.

This study reported that while no effective treatment exists for frontal fibrosing alopecia, oral 5-alpha-reductase inhibitors showed the most promise, inducing a good clinical response in 45% of patients.

This study found that human liver dehydroepiandrosterone sulfotransferase (DHEA ST) catalyzes the sulfate conjugation of minoxidil, indicating another pathway contributing to its metabolism in humans.

This study investigated the effects of heat-treated Limosilactobacillus fermentum LM1020 on hair growth and reported increased hair density, improved cellular activity, and beneficial scalp microbiota changes in patients with androgenetic alopecia over 24 weeks.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.

This study found that two synthesized androst-4-ene-3-one derivatives, 6f and 6g, exhibited stronger anti-proliferative effects than common drugs on prostate cancer cell lines, with low toxicity to rat cells.

In this study, an oleanolic acid-containing scalp treatment increased terminal hair counts significantly more than placebo in men under 50 with androgenic alopecia, but only three showed clinical improvement, with minimal side effects reported.

In this study, trilostane treatment led to complete hair re-growth in 85% of Pomeranians and all miniature poodles with alopecia X within 4 to 8 weeks.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.